PANK2 Polyclonal Antibody, HRP Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-8338R-HRP-100uL |
| Product Name | PANK2 Polyclonal Antibody, HRP Conjugated |
| Applications |
WB
ELISA
IHC-P
IHC-F
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat, Dog, Cow, Pig, Horse |
| Specifications | |
| Conjugation | HRP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human PANK2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 80025 |
| Swiss Prot | Q9BZ23 |
| Subcellular location | Cytoplasm |
| Synonyms | Pantothenate kinase 2, mitochondrial; hPanK2; Pantothenic acid kinase 2; PANK2; C20orf48; PANK2_HUMAN |
| Background | Defects in PANK2 are the cause of neurodegeneration with brain iron accumulation type 1 (NBIA1); also known as pantothenate kinase-associated neurodegeneration (PKAN) or Hallervorden-Spatz syndrome (HSS). It is an autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in the first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in the second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in the first decade with slow progression or onset in the second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI.Defects in PANK2 are the cause of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP). HARP is a rare syndrome with many clinical similarities to NBIA1. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
Frequently asked questions
Which applications is PANK2 Polyclonal Antibody, HRP Conjugated (bs-8338R-HRP) validated for, and at what dilution?
bs-8338R-HRP is validated for WB (1:300-5000); ELISA (1:500-1000); IHC-P (1:200-400); IHC-F (1:100-500). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does PANK2 Polyclonal Antibody, HRP Conjugated (bs-8338R-HRP) react with?
Tested reactivity: Human, Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Rat, Dog, Cow, Pig, Horse.
How should bs-8338R-HRP be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise PANK2 Polyclonal Antibody, HRP Conjugated (bs-8338R-HRP)?
KLH conjugated synthetic peptide derived from human PANK2